Swartz Robin 4

What Happened

• Robin Swartz, Chief Operating Officer & Chief Business Officer of Voyager Therapeutics (VYGR), sold 4,569 shares on 2026-02-10 at a weighted-average price of $3.85, for proceeds of about $17,591. This was a sale (not a purchase) and was executed as a sell-to-cover to satisfy tax withholding tied to RSU vesting, not a discretionary trade.

Key Details

• Transaction date: 2026-02-10; weighted-average price reported $3.85.
• Price range: shares sold in multiple transactions at prices from $3.72 to $3.90 (per filing footnote).
• Reason: Sell-to-cover to satisfy tax withholding for RSUs that vested on 2026-02-09 (footnote indicates sales were not discretionary).
• Shares owned after the transaction: not specified in the excerpt provided (see full Form 4 for total beneficial ownership).
• Filing timeliness: Form 4 filed 2026-02-11 (next day), i.e., timely.

Context

• The sale was a routine sell-to-cover associated with restricted stock unit vesting (tax withholding), which is common and does not necessarily indicate an insider's change in view on the company. The filer can provide a breakdown of the number of shares sold at each price in the $3.72–$3.90 range upon request.